Portola Pharmaceuticals Inc (PTLA): William Lis , Chief Executive Officer of Portola Pharmaceuticals Inc sold 5,675 shares on May 2, 2016. The Insider selling transaction was reported by the company on May 3, 2016 to the Securities and Exchange Commission. The shares were sold at $23.86 per share for a total value of $135,405.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 21, 2015, Mardi Dier (Executive VP and CFO) sold 8,912 shares at $55.00 per share price.On Sep 18, 2015, Charles J Homcy (director) sold 40,067 shares at $56.25 per share price.Also, On Jul 15, 2015, William Lis (Chief Executive Officer) sold 50,000 shares at $50.00 per share price.On Jul 15, 2015, John T Curnutte (Executive Vice President) sold 10,000 shares at $50.00 per share price.
Portola Pharmaceuticals Inc: On Monday, May 2, 2016 heightened volatility was witnessed in Portola Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $23.86 and hit $24.5 on the upside , eventually ending the session at $24.45, with a gain of 2.90% or 0.69 points. The heightened volatility saw the trading volume jump to 6,14,296 shares. The 52-week high of the share price is $57.955 and the company has a market cap of $1,378 M . The 52-week low of the share price is at $18.2.
Company has been under the radar of several Street Analysts.Portola Pharmaceuticals Inc is Downgraded by Goldman to Neutral while Lowering the Price Target of the company shares to $ 30 from a previous price target of $65 . Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Mar 28, 2016.Portola Pharmaceuticals Inc is Reiterated by Credit Suisse to Outperform while Lowering the Price Target of the company shares to $ 34 from a previous price target of $47 . The Rating was issued on Mar 28, 2016.
Portola Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Companys two lead programs Betrixaban and Andexanet alfa address unmet medical needs in the area of thrombosis or blood clots. Its third product candidate is Cerdulatinib. The Company has a program of selective Syk inhibitors which is partnered with Biogen Idec Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa. Andexanet alfa is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. Cerdulatinib is an orally available potent dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.